PILOT PROJECT

120+ MEDICINAL PRODUCTS INCLUDED

RESILIX

HOSPITAL USE ONLY

84 MONTHS

WHAT

Medicinal products switch Leaflet (PIL) to **Electronic Patient** Information Leaflet (e-PIL).

To demonstrate that the e-PIL is WHY

equivalent to the paper PIL in providing information on safe and effective use of the medicines to the patients and healthcare professionals (HCPs) in hospital setting.

WHERE 3 →

In the Belgium and Luxembourg market, products with a restricted use HOW

The e-PIL is available on several trusted sources online. The Belgian and Luxembourg Competent Authorities and authorised by the

WHEN

Initially launched on 1 August 2018, for a 24-month period, the project has been extended until 1 August 2025.



FROM PAPER

TO ELECTRONIC



VALUATION OF THE PILO

SURVEY FOR HOSPITAL PHARMACISTS TO EVALUATE THE ACCESS, THE USE AND THE READING OF THE E-PIL

BASELINE RESULTS (2018) T=0M

72%

72 % of responding hospital pharmacists consult the PIL on a daily or weekly basis to answer questions of HCPs or for pharmaceutical/ prescription validation.

75%

For this purpose, 75 % of hospital pharmacists already consult the e-PIL.

37%

37 % of responding hospital pharmacists are consulted by physicians on a daily, weekly, or monthly basis.

Patients very rarely solicit the hospital pharmacists to receive the PIL.



FINAL RESULTS (2024) T=72M

When responding hospital pharmacists have had to consult the PIL of participating medicines:

97%

97 % consulted the e-PIL **version** and 3 % printed the leaflet from an online source.

97%

97 % would agree that the PIL is removed from the packaging of the medicines restricted to hospital use.

Confirmation that patients solicit very rarely the hospital pharmacists to receive the PIL.

100%

100 % declare that the absence of the paper PIL in the packaging has not caused any inconvenience

in their daily practice. Moreover, according to **100** % of the hospital pharmacists, the absence did not cause any inconvenience to physicians and for **97** % of the hospital pharmacists, the absence did not cause any inconvenience to nurses.



SURVEY FOR PARTICIPATING PHARMA COMPANIES TO EVALUATE THE QUESTIONS RECEIVED DUE TO THE ABSENCE OF THE PAPER PIL

FINAL RESULTS (2024) T=72M

- Aggregated total of minimum 4 290 712 sold units throughout the pilot project.
- Only **12 questions** related to the absence of the paper PIL submitted by the healthcare professionals to the participating pharma companies.

CONCLUSION & NEXT STEPS

- restricted to hospital use from 27 pharmaceutical companies are included without paper PIL in the packaging until 1 August 2025.
- The project demonstrated that, in hospital setting, the e-PIL is just as effective to the paper PIL in delivering information on a safe and effective use of medicines by hospital in their daily practice.
- the change in EU pharmaceutical legislation regarding the transition from paper PIL to e-PIL, implemented through a step-wise approach, starting in the hospital.

PARTICIPATING **COMPANIES**

(NON-EXHAUSTIVE)
























































Romain Labé contact@iml.lu



Antoon Daneels antoon.daneels@medaxes.be







maa.hum@ms.etat.lu